Advertisement
Advertisement
BOLT
Bolt Biotherapeutics, Inc. Common Stock
6.30
USDSponsored
-0.13
-2.02%
Nov 10, 15:58 UTC -5
Closed
After-Market
6.28
-0.02
-0.40%
Bolt Biotherapeutics, Inc. Common Stock (BOLT) Earnings
BOLT Earnings Reports
Positive Surprise Ratio
BOLT beat 16 of 23 last estimates.
70%
Next Report
Today
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$3.75
Implied change from Q2 26 (Revenue/ EPS)
-100.00%
/-17.94%
Implied change from Q3 25 (Revenue/ EPS)
-100.00%
/+0.81%
Bolt Biotherapeutics, Inc. Common Stock earnings per share and revenue
On Aug 11, 2026, BOLT reported earnings of -4.57 USD per share (EPS) for Q2 26, missing the estimate of -3.45 USD, resulting in a -32.30% surprise. Revenue reached 5.00 thousand, compared to an expected 510.00 thousand, with a -99.02% difference. The market reacted with a -13.32% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -3.75 USD, with revenue projected to reach -- USD, implying an decrease of -17.94% EPS, and decrease of -100.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
CalciMedica, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.30
Actual
-$0.72
Surprise
+44.64%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
FAQ
What were Bolt Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Bolt Biotherapeutics, Inc. Common Stock reported EPS of -$4.57, missing estimates by -32.3%, and revenue of $5.00K, -99.02% below expectations.
How did the market react to Bolt Biotherapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -13.32%, changed from $3.98 before the earnings release to $3.45 the day after.
When is Bolt Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Bolt Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 4
analysts, Bolt Biotherapeutics, Inc. Common Stock is expected to report EPS of -$3.75 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.